We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A New Way to Treat Type 1 and Type 2 Diabetes?
News

A New Way to Treat Type 1 and Type 2 Diabetes?

A New Way to Treat Type 1 and Type 2 Diabetes?
News

A New Way to Treat Type 1 and Type 2 Diabetes?

Islets of Langerhans containing MANF-expressing β-cells (red) contain more insulin-containing β-cells (green) (A) than those that lack MANF-expressing β-cells (B). Credit: MARIA LINDAHL
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "A New Way to Treat Type 1 and Type 2 Diabetes?"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MANF has therapeutic potential for the treatment of Type 1 and Type 2 diabetes.

Diabetes mellitus is characterised by high blood glucose levels. These high levels are caused by the inability of the insulin-producing β-cells in the pancreas to maintain sufficient levels of circulating insulin.

Current medications alleviate diabetic symptoms, but they cannot reconstitute physiological insulin secretion. This increases the risk of vascular complications, which might lead to conditions such as heart disease, stroke and kidney disease. 

Typical for Type 1 and the later stages of Type 2 diabetes is β-cell loss preceded by sustained cell stress. The stress is caused by problems in dealing with aggregated proteins that lead to the self-destruction of β-cells.

One of the main goals in improving current diabetes therapy is to find ways to protect β-cells from stress and activate their regeneration.

Maria Lindahl and her team at the University of Helsinki have found that the removal of mesencephalic astrocyte–derived neurotrophic factor MANF specifically from β-cells in adult mice results in the loss of β-cells in diabetes.

"This indicates that MANF expression is needed for the survival, maintenance and function of pancreatic β-cells in mice. MANF was also found to protect stressed β-cells from death and to induce the proliferation of β-cells from old mice," Maria Lindahl says.

“This discovery further suggests that MANF has therapeutic potential for the treatment of Type 1 and Type 2 diabetes, where β-cell protecting and regenerating therapies are not available,” says Tatiana Danilova from Maria Lindahl's team.

In previous collaboration studies at the University of Helsinki by the groups directed by Professor Mart Saarma and Professor Timo Otonkoski, MANF deficiency in mice led to diabetes due to the progressive loss of insulin-producing pancreatic β-cells. MANF was found to be important for the survival and proliferation of both human and mouse β-cells in culture.

This article has been republished from materials provided by University of Helsinki. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference

Danilova T, Belevich I, Li H, Palm E, Jokitalo E, Otonkoski T, Lindahl M. MANF is required for the postnatal expansion and maintenance of the pancreatic β-cell mass in mice.  Diabetes. (2018) Oct 10. pii: db171149. doi: 10.2337/db17-1149 

 

Advertisement